Results of three Phase II trials with the long-acting β2-adrenergic agonist (LABA) abediterol in patients with persistent asthma

Introduction: Efficacy and safety of abediterol (LAS100977), a novel LABA in development as a fixed dose combination with an inhaled corticosteroid for the treatment of asthma and COPD, were investigated in 3 Phase II trials in patients with persistent, stable asthma. Methods: Randomized, double-blind, placebo-controlled, crossover designs were used. Single doses (dose range: 0.313 to 25 µg) of abediterol were administered in the morning via Cyclohaler® (Study 1 and 2) or Genuair® (Study 3). In studies 1 and 3, active comparators (salmeterol and salbutamol, respectively) were used. Change from baseline in FEV1 w…